Arbor Biosciences, Medicinal Genomics Partner on Marker Discovery and Genotyping in Cannabis

Arbor Biosciences, a division of Chiral Technologies, Inc. and worldwide leader in next generation sequencing (NGS) target enrichment, today announced a partnership with Medicinal Genomics Corp. (MGC), a pioneer in genomics that improves the yield, safety, and transparency of cannabis, to introduce a new genotyping panel for cannabis.

Written byArbor Biosciences
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

Together the organizations will use their extensive resources for genetic testing and to create a cannabis genome knowledge bank to generate a comprehensive panel for analyzing unique genetic signatures in cannabis strains.

Building upon their updated reference genome of the Jamaican Lion cultivar, and a recently announced pan-genome project with PacBio, MGC has identified the genetic variations that cause a plant to produce the important cannabinoids of THC, CBD, and their combinations, referred to as chemotypes (I-IV). This information provides a genetic fingerprint for different types and cultivars, and is a key to selective breeding of cannabis.

Using markers identified by MGC, Arbor has designed and developed a hybridization-based capture panel for targeted NGS sequencing. The myBaits®-based panel utilizes proprietary software to design unique probes that are complementary to the genetic sequences of interest, which are then reproduced on Arbor’s massively parallel synthesis platform. The system provides an extremely efficient ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here
Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies